As we bring back Managed Healthcare Executive's "Meet the Board" podcast series, MHE welcomes its newest Editorial Advisory Board member Greg Baker, CEO of AffirmedRx.
As we bring back our "Meet the Board" Series podcast series, Managed Healthcare Executive welcomes our newest Editorial Advisory Board member Greg Baker, CEO of AffirmedRx. In this conversation, Baker and Peter Wehrwein, MHE managing editor, discussed insights from Baker's career journey, particularly his tenure at Walgreens, where he gained insights into operational efficiency and patient care.
Baker highlighted the importance of process orientation and patient-centered care, drawing from his experience as a pharmacist.
He also dove into his time at Premise Health, highlighting their service-oriented model focused on improving adherence and patient outcomes. He contrasted this with traditional PBMs' profit-driven approaches, expressing concerns about opaque pricing practices and exclusionary formularies.
AffirmedRx, a public benefit corporation, aims to bring transparency to the PBM industry by disclosing all financial terms to clients. Baker discussed their unique approach, which includes a cloud-based system, patient care advocates, and a clinically-driven formulary that prioritizes cost-effectiveness and clinical utility over rebates.
He expressed skepticism about legislative solutions, suggesting that current proposals may not address the root causes of industry issues. AffirmedRx is part of TransparencyRx, a collective advocating for industry reform.
Looking ahead, Baker warned against the proliferation of corporate entities within PBMs, which could further obscure pricing practices and hinder transparency efforts. He underscored the importance of educating stakeholders and advocating for meaningful reform within the industry.
FDA Updates for Week of May 13: First Bispecific Antibody for Solid Tumor
May 18th 2024The FDA has approved a new type of bispecific antibody to treat small cell lung cancer and an additional indication for Breyanzi for patients with follicular lymphoma. The agency has set review date for gene therapy for enzyme deficiency. In addition, Biogen have Eisai hve begun a rolling submission of subcutaneous Leqembi for Alzheimer’s disease.
Read More
Omega-3s For Dry Eye Disease? Not the Answer According to This Study
May 17th 2024Some research has suggested that omega-3 fatty acid supplements could help treat dry eye disease. But Korean investigators reported results from a randomized clinical trial this week in JAMA Ophthalmology tthat showed no benefit.
Read More